| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
HEP-2 SUBSTRATE ANTINUCLEAR ANTIBODIES, SERUM
Test CodeLAB147
CPT Codes
86038
Preferred Specimen
One 5 mL gold top tube
Minimum Volume
Required for Testing: 0.8 mL serum
Instructions
Sample must be centrifuged within 1 hour of collection and aliquot 0.8 mL of serum.
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated: 72 hours Frozen: not specified
Methodology
Immunofluorescence, Automated
Setup Schedule
Monday-Friday, day shift
Reference Range
Negative
Clinical Significance
Diagnosis of autoimmune diseases by rheumatology specialists. The primary test used to evaluate patients with suspected systemic
rheumatic disease is ANTINUCLEAR ANTIBODIES (ANA), SERUM performed by IFA.
Initial screening dilution is 1:80. If the test result is negative, no additional testing is performed and the Negative result is reported.
Positive 1:80 titers get endpoint titration up to 1:5120; beyond that, the titer is reported as ">1:5120". Positive results are reported with titer
and pattern information. Cytoplasmic staining will be noted in result comments when identified, but is not anti-nuclear staining, so renders the ANA result Negative, Cytoplasmic fluorescence noted.
Positive ANA results must be interpreted along with clinical and other laboratory findings. Follow-up testing with appropriate subserology (ie,
dsDNA, chromatin, centromere, SS-A/Ro, SS-B/La, Scl-70, Jo-1, RNP, and ribosome P antibodies is suggested as clinically indicated.
rheumatic disease is ANTINUCLEAR ANTIBODIES (ANA), SERUM performed by IFA.
Initial screening dilution is 1:80. If the test result is negative, no additional testing is performed and the Negative result is reported.
Positive 1:80 titers get endpoint titration up to 1:5120; beyond that, the titer is reported as ">1:5120". Positive results are reported with titer
and pattern information. Cytoplasmic staining will be noted in result comments when identified, but is not anti-nuclear staining, so renders the ANA result Negative, Cytoplasmic fluorescence noted.
Positive ANA results must be interpreted along with clinical and other laboratory findings. Follow-up testing with appropriate subserology (ie,
dsDNA, chromatin, centromere, SS-A/Ro, SS-B/La, Scl-70, Jo-1, RNP, and ribosome P antibodies is suggested as clinically indicated.
Performing Laboratory
West Virginia University Hospital, Inc.
